Skip to main content
SpringerLink
Log in

Complications of Retinopathy of Prematurity Treatment

  • Chapter
  • First Online:
Retinopathy of Prematurity

Abstract

Although major progress has been made in the management of retinopathy of prematurity (ROP), complications arising from various treatment applications are common and require careful monitoring and surveillance. In this chapter, we summarize the complications associated with the use of cryotherapy, laser photocoagulation, anti-vascular endothelial growth factor agents, scleral buckle, and vitrectomy in the treatment of ROP. While some complications are acute, others may not develop until many years later. The timing when these complications arise, during active or chronic stage, also varies. Proper management should be delivered once these complications are identified.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Good WV. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–48.

    PubMed  PubMed Central  Google Scholar 

  2. Wu WC, Lin RI, Shih CP, et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmol. 2012;119:1907–16.

    Article  Google Scholar 

  3. Tasman W, Patz A, McNamara JA, et al. Retinopathy of prematurity: the life of a lifetime disease. Am J Ophthalmol. 2006;141:167–74.

    Article  PubMed  Google Scholar 

  4. Tufail A, Singh AJ, Haynes RJ, et al. Late onset vitreoretinal complications of regressed retinopathy of prematurity. Br J Ophthalmol. 2004;88:243–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Summers G, Phelps DL, Tung B, Palmer EA. Ocular cosmesis in retinopathy of prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1992;110:1092–7.

    Article  CAS  PubMed  Google Scholar 

  6. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1988;106:471–9.

    Google Scholar 

  7. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1990;108:195–204.

    Google Scholar 

  8. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome–structure and function. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol. 1990;108:1408–16.

    Google Scholar 

  9. Simpson JL, Melia M, Yang MB, et al. Current role of cryotherapy in retinopathy of prematurity: a report by the American academy of ophthalmology. Ophthalmol. 2012;119:873–7.

    Article  Google Scholar 

  10. Jalali S, Azad R, Trehan HS, et al. Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia. Indian J Ophthalmol. 2010;58:509–15.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmol. 2009.

    Google Scholar 

  12. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmol. 2009;116:1599–603.

    Article  Google Scholar 

  13. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177–82.

    Article  PubMed  Google Scholar 

  14. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmol. 2007;114:855–9.

    Article  Google Scholar 

  15. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmol. 2007;114:2179–82.

    Article  Google Scholar 

  16. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina. 2010;30:S24–31.

    Article  PubMed  Google Scholar 

  17. Lin CJ, Chen SN, Hwang JF. Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity. Oman J Ophthalmol. 2012;5:184–6.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity. N Engl J Med. 2011;364:603–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mota A, Carneiro A, Breda J, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol. 2012;3:136–41.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013;97:816–9.

    Article  PubMed  Google Scholar 

  21. Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155:150–8.

    Article  CAS  PubMed  Google Scholar 

  22. Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmol. 2011;118:1227–8.

    Google Scholar 

  23. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33.

    Article  CAS  PubMed  Google Scholar 

  24. Wu WC, Lai CC, Chen KJ, et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci. 2010;51:3701–8.

    Article  PubMed  Google Scholar 

  25. Sakowski SA, Heavener SB, Lunn JS, et al. Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression. Gene Ther. 2009;16:1292–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Been JV, Zoer B, Kloosterboer N, et al. Pulmonary vascular endothelial growth factor expression and disaturated phospholipid content in a chicken model of hypoxia-induced fetal growth restriction. Neonatology. 2010;97:183–9.

    Article  CAS  PubMed  Google Scholar 

  27. Yamamoto C, Yagi S, Hori T, et al. Significance of portal venous VEGF during liver regeneration after hepatectomy. J Surg Res. 2010;159:e37–43.

    Article  PubMed  Google Scholar 

  28. Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33:329–38.

    Article  CAS  PubMed  Google Scholar 

  29. Banker AS, Banker DA. Anatomical, functional, OCT and neurodevelopmental analysis outcomes of intravitreal bevacizumab injection without laser for retinopathy of prematurity: 6 year follow-up. 2013.

    Google Scholar 

  30. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009;148:536–43.

    Article  CAS  PubMed  Google Scholar 

  31. Harder BC, Schlichtenbrede FC, von BS, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol. 2013;155:1119–24.

    Article  CAS  PubMed  Google Scholar 

  32. Smith EL III. Prentice award lecture 2010: a case for peripheral optical treatment strategies for myopia. Optom Vis Sci. 2011;88:1029–44.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Chuang YC, Yang CM. Scleral buckling for stage 4 retinopathy of prematurity. Ophthalmic Surg Lasers. 2000;31:374–9.

    CAS  PubMed  Google Scholar 

  34. Ricci B, Santo A, Ricci F, et al. Scleral buckling surgery in stage 4 retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 1996;234(Suppl 1):S38–41.

    Article  PubMed  Google Scholar 

  35. Wu WC, Lai CC, Lin RI, et al. Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity. Arch Ophthalmol. 2011;129:1326–31.

    Article  PubMed  Google Scholar 

  36. Lakhanpal RR, Sun RL, Albini TA, Holz ER. Anatomical success rate after primary three-port lens-sparing vitrectomy in stage 5 retinopathy of prematurity. Retina. 2006;26:724–8.

    Article  PubMed  Google Scholar 

  37. Imaizumi A, Kusaka S, Noguchi H, et al. Efficacy of short-term postoperative perfluoro-n-octane tamponade for pediatric complex retinal detachment. Am J Ophthalmol. 2014;157:384–9.

    Article  CAS  PubMed  Google Scholar 

  38. Sisk RA, Berrocal AM, Murray TG, Mavrofrides EC. Extended endotamponade with perfluoro-n-octane in pediatric retinal detachment. Ophthalmic Surg Lasers Imaging. 2010;1–3.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology, Chang Gung Memorial Hospital, No. 5, Fu-Hsin St., Kweishan, Taoyuan, 333, Taiwan

    Wei-Chi Wu

  2. Department of Ophthalmology, Shiley Eye Institute, University of California, San Diego, 9415 Campus Point Drive, La Jolla, CA, 92093, USA

    Jane Z. Kuo

Authors
  1. Wei-Chi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Z. Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei-Chi Wu .

Editor information

Editors and Affiliations

  1. KYDOFT, Santiago, Chile

    Andrés Kychenthal B.

  2. KYDOFT, Santiago, Chile

    Paola Dorta S.

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Wu, WC., Kuo, J.Z. (2017). Complications of Retinopathy of Prematurity Treatment. In: Kychenthal B., A., Dorta S., P. (eds) Retinopathy of Prematurity. Springer, Cham. https://doi.org/10.1007/978-3-319-52190-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52190-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52188-6

  • Online ISBN: 978-3-319-52190-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation